Protagonist Therapeutics PTGX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's retained earnings?
- Protagonist Therapeutics (PTGX) reported retained earnings of -$466.89M in Q1 2026.
- How has Protagonist Therapeutics's retained earnings changed year-over-year?
- Protagonist Therapeutics's retained earnings decreased by 32.6% year-over-year, from -$352.18M to -$466.89M.
- What is the long-term trend for Protagonist Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's retained earnings has grown at a 10.6% compound annual growth rate (CAGR), from -$283.81M to -$470.67M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.